Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Annals of Oncology (Impact Factor: 7.38). 02/2008; 19(2):315-20. DOI: 10.1093/annonc/mdm429
Source: PubMed

ABSTRACT AKT phosphorylation is a critical step in the activation of growth factor receptors and can mediate tumor resistance to anthracyclines. We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues.
pAKT expression was assessed by immunohistochemistry in 823 tumors from patients with early breast cancer enrolled in two randomized trials. The distribution of pAKT expression was correlated with HER2 and epidermal growth factor receptor (EGFR) expression. The predictive value of pAKT for the efficacy of adjuvant chemotherapy was determined by test for interaction.
pAKT, EGFR, and HER2 were expressed in 119 of 781 (15%), 118 of 758 (16%), and 99 of 775 (13%) assessable tumors. Staining was positive for pAKT in 28 of 99 (28%) and 90 of 676 (13%) HER2+ and HER2- tumors (P < 0.001). pAKT was expressed in 15 of 94 (16%) and 75 of 563 (13%) HER2-/EGFR+ and HER2-/EGFR- tumors, respectively (P = 0.49). A positive staining for pAKT did not correlate with prognosis (P = 0.94), and did not predict the resistance to anthracyclines (test for interaction, P = 0.70).
AKT phosphorylation is associated with HER2 expression but not EGFR expression in patients with early breast cancer. pAKT is not predictive for the efficacy of anthracycline-based adjuvant chemotherapy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: CD44v6 contributes to apoptosis resistance and metastasis via upregulated activity of the PI3K/AKT pathway. The purpose of this study was to investigate the expression patterns and predictive value of phosphorylated AKT (pAKT) and CD44v6 in breast cancer tissues. Expression of pAkt and CD44v6 protein was detected using immunohistochemistry in breast cancer tissues and lymph node tissues in 98 patients. The correlation between the expression of pAkt, CD44v6 and other disease-related characteristics was investigated. The prognostic value of pAKT and CD44v6 overexpression for overall survival (OS) and disease free survival (DFS) was determined. 37 cases (37.8%) were observed as positive for pAkt expression, and 38 cases (38.8%) for CD44V6 overexpression. Staining was positive for pAKT in 20 of 38 (52.6%) CD44v6(+) and 17 of 60 (28.3%) CD44v6(-) (P = 0.016). A progressively increased trend of CD44v6 overexpression was observed from node(-) primary breast cancer tissues to node(+) primary cancer tissues to node(+) lymph tissues (P = 0.000). In univariate analysis lymph node status, pAKT and CD44V6 were significantly associated with a decreased OS and DFS. Multivariate analysis revealed that CD44v6 status was associated with a reduced OS (P = 0.003), and pAKT and CD44v6 with a shorter DFS (P = 0.012 and 0.016, respectively). Our data suggested that there had an intensive relationship between pAKT and CD44v6 expression in breast cancer tissues. The overexpression of CD44v6 was an independent prognostic marker for predicting OS and DFS of breast cancer patients.
    Journal of Cancer Research and Clinical Oncology 02/2010; 136(8):1283-92. · 2.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rapamycin is a selective inhibitor of the mammalian target of rapamycin (mTOR), a regulator kinase that integrates growth factors signaling via the phosphoinositide-3-kinase pathway and that has emerged as a novel therapeutic modality in breast cancer (BC). We propose a pre-clinical "ex-vivo" personalized organotypic culture of BC that preserves the microenvironment to evaluate rapamycin-mediated gene expression changes. Freshly excised ductal invasive BC slices, 400 μm thick (n=30), were cultured in the presence or absence (control) of rapamycin (20 nM) for 24 h. Some slices were formalin-fixed for immunohistochemical determinations and some were processed for microarray analysis. Control slices in culture retained their tissue morphology and tissue viability (detected by BrdU uptake). The percentage of proliferating cells (assessed by Ki67) did not change up to 24 h of treatment. Immunohistochemical evaluation of p-AKT, p-mTOR, p-4EBP1 and p-S6K1 indicated that AKT/mTOR pathway activation was maintained during cultivation. For microarray analysis, slices were divided into two groups, according to the presence/absence of epidermal growth factor receptor-type 2 and analyzed separately. Limited overlap was seen among differentially expressed genes after treatment (P<0.01) in both groups suggesting different responses to rapamycin between these BC subtypes. Ontology analysis indicated that genes involved in biosynthetic processes were commonly reduced by rapamycin. Our network analysis suggested that concerted expression of these genes might distinguish controls from treated slices. Thus, breast carcinoma slices constitute a suitable physiological tool to evaluate the short-term effects of rapamycin on the gene profile of individual BC samples.
    Cell and Tissue Research 05/2013; · 3.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Les progrès des analyses biologiques ont permis de sous classer les cancers du sein en différentes entités moléculaires, et d’identifier un panel de cibles thérapeutiques candidates. L’identification de ces cibles impose, dorénavant, d’évaluer chaque médicament dans des populations définies par les analyses moléculaires. Ce changement dans le développement des médicaments pose un certain nombre de problèmes. Tout d’abord, il impose, dorénavant, de tester les médicaments dans des maladies moléculaires rares. Ensuite, il nécessite la mise au point de tests moléculaires, dont le nombre élevé pourrait à terme être un frein. Enfin, il pose le problème de l’organisation des soins autour des analyses moléculaires. Dans cette revue, nous décrirons dans un premier temps les différentes cibles thérapeutiques candidates observées dans le cancer du sein, puis nous discuterons les implications du développement de la médecine personnalisée par les analyses moléculaires. The advances in biologic analyses based on gene expression profiling have allowed the classification breast cancers into four different diseases. Also, molecular analyses have allowed the identification of a number of candidate therapeutic targets. Such identification requires, now, the evaluation of each targeted agent in biologically-selected populations. Such changes in the model of drug development induce a number of implications. First, targeted agents will have to be developed for rare molecular diseases. Second, such model of development will require the launch of bioassay for each molecular alteration. In this review, we will first present the most frequent “targetable” genomic alterations observed in breast cancers. Then, we will discuss the implications in terms of development of targeted agents. Mots clésPrédicteur génomique pronostique-Biomarqueur prédictif-Cancer du sein KeywordsGene expression predictor-Breast cancer-DNA array
    Oncologie 01/2010; 12(4):274-277. · 0.10 Impact Factor


1 Download